Geulah Livshits
Stock Analyst at Chardan Capital
(1.14)
# 3,359
Out of 4,810 analysts
187
Total ratings
24.02%
Success rate
-13.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $50 | $23.93 | +108.94% | 1 | Apr 9, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Buy | $25 → $22 | $2.55 | +762.75% | 8 | Apr 8, 2025 | |
| IPSC Century Therapeutics | Maintains: Buy | $11 → $7 | $0.50 | +1,297.21% | 5 | Mar 24, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 | $1.29 | +907.75% | 10 | Mar 24, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $15 → $16 | $1.32 | +1,112.12% | 4 | Mar 20, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 → $9 | $0.51 | +1,673.75% | 10 | Mar 12, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $16 | $2.70 | +492.59% | 6 | Mar 7, 2025 | |
| PASG Passage Bio | Maintains: Buy | $7 → $6 | $0.37 | +1,526.02% | 4 | Mar 4, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $30 → $28 | $3.10 | +803.23% | 8 | Mar 4, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $34 → $30 | $3.23 | +828.79% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $54 | $6.53 | +726.95% | 15 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $91 → $68 | $7.36 | +823.91% | 13 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 | $1.27 | +451.18% | 12 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $212 → $218 | $169.13 | +28.89% | 9 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $94 → $84 | $38.95 | +115.66% | 12 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.55 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.35 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $12 | $3.67 | +226.98% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $1.57 | +855.41% | 5 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $5.45 | +652.29% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $4.37 | +472.08% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.12 | +971.43% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $26.24 | +692.68% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.11 | +1,341.44% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $2.5 | $6.95 | -64.00% | 5 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $6.55 | +1,274.05% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.21 | +24.61% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $600 | $0.28 | +218,081.82% | 2 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $3.23 | +828.79% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $7.40 | +143.24% | 1 | Oct 27, 2020 |
Palvella Therapeutics
Apr 9, 2025
Initiates: Buy
Price Target: $50
Current: $23.93
Upside: +108.94%
Lexeo Therapeutics
Apr 8, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $2.55
Upside: +762.75%
Century Therapeutics
Mar 24, 2025
Maintains: Buy
Price Target: $11 → $7
Current: $0.50
Upside: +1,297.21%
Immuneering
Mar 24, 2025
Maintains: Buy
Price Target: $13
Current: $1.29
Upside: +907.75%
Prime Medicine
Mar 20, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $1.32
Upside: +1,112.12%
Tenaya Therapeutics
Mar 12, 2025
Maintains: Buy
Price Target: $18 → $9
Current: $0.51
Upside: +1,673.75%
Solid Biosciences
Mar 7, 2025
Maintains: Buy
Price Target: $16
Current: $2.70
Upside: +492.59%
Passage Bio
Mar 4, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.37
Upside: +1,526.02%
4D Molecular Therapeutics
Mar 4, 2025
Maintains: Buy
Price Target: $30 → $28
Current: $3.10
Upside: +803.23%
Iovance Biotherapeutics
Mar 3, 2025
Maintains: Buy
Price Target: $34 → $30
Current: $3.23
Upside: +828.79%
Feb 28, 2025
Maintains: Buy
Price Target: $62 → $54
Current: $6.53
Upside: +726.95%
Feb 28, 2025
Maintains: Buy
Price Target: $91 → $68
Current: $7.36
Upside: +823.91%
Feb 26, 2025
Maintains: Buy
Price Target: $7
Current: $1.27
Upside: +451.18%
Feb 20, 2025
Maintains: Buy
Price Target: $212 → $218
Current: $169.13
Upside: +28.89%
Feb 13, 2025
Maintains: Buy
Price Target: $94 → $84
Current: $38.95
Upside: +115.66%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.55
Upside: -
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Dec 4, 2024
Maintains: Buy
Price Target: $10 → $12
Current: $3.67
Upside: +226.98%
Nov 20, 2024
Maintains: Buy
Price Target: $15
Current: $1.57
Upside: +855.41%
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $5.45
Upside: +652.29%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $4.37
Upside: +472.08%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.12
Upside: +971.43%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $26.24
Upside: +692.68%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.11
Upside: +1,341.44%
Aug 22, 2022
Maintains: Buy
Price Target: $4 → $2.5
Current: $6.95
Upside: -64.00%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $6.55
Upside: +1,274.05%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.21
Upside: +24.61%
Aug 13, 2021
Maintains: Buy
Price Target: $660 → $600
Current: $0.28
Upside: +218,081.82%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $3.23
Upside: +828.79%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $7.40
Upside: +143.24%